Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 575

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Opioid-induced Hyperalgesia in Humans: Molecular Mechanisms and Clinical Considerations

Chu, Larry F., Angst, Martin S., Clark, David·2008·The Clinical Journal of Pain

Abstract

Opioid-induced hyperalgesia (OIH) is most broadly defined as a state of nociceptive sensitization caused by exposure to opioids. The state is characterized by a paradoxical response whereby a patient receiving opioids for the treatment of pain may actually become more sensitive to certain painful stimuli. The type of pain experienced may or may not be different from the original underlying painful condition. Although the precise molecular mechanism is not yet understood, it is generally thought to result from neuroplastic changes in the peripheral and central nervous systems that lead to sensitization of pronociceptive pathways. OIH seems to be a distinct, definable, and characteristic phenomenon that may explain loss of opioid efficacy in some cases. Clinicians should suspect expression of OIH when opioid treatment effect seems to wane in the absence of disease progression, particularly if found in the context of unexplained pain reports or diffuse allodynia unassociated with the pain as previously observed. This review highlights the important mechanistic underpinnings and clinical ramifications of OIH and discusses future research directions and the latest clinical evidence for modulation of this potentially troublesome clinical phenomenon.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/ajp.0b013e31816b2f43

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 164

  1. Krjtikos, 1967, The history of poppy and of opium and their expansion in antiquity, Bull Narc, 3, 17
  2. Gimbel, 2003, Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial, Neurology, 60, 927, 10.1212/01.WNL.0000057720.36503.2C · DOI · Paper page
  3. Raja, 2002, Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial, Neurology, 59, 1015, 10.1212/WNL.59.7.1015 · DOI · Paper page
  4. Rowbotham, 2003, Oral opioid therapy for chronic peripheral and central neuropathic pain, N Engl J Med, 348, 1223, 10.1056/NEJMoa021420 · DOI · Paper page
  5. Watson, 2003, Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy, Pain, 105, 71, 10.1016/S0304-3959(03)00160-X · DOI · Paper page
  6. Dellemijn, 1997, Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain, Lancet, 349, 753, 10.1016/S0140-6736(96)09024-1 · DOI · Paper page
  7. Caldwell, 1999, Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial, J Rheumatol, 26, 862
  8. Roth, 2000, Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation, Arch Intern Med, 160, 853, 10.1001/archinte.160.6.853 · DOI · Paper page
  9. Moulin, 1996, Randomised trial of oral morphine for chronic non-cancer pain, Lancet, 347, 143, 10.1016/S0140-6736(96)90339-6 · DOI · Paper page
  10. Arkinstall, 1995, Efficacy of controlled-release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trial, Pain, 62, 169, 10.1016/0304-3959(94)00262-D · DOI · Paper page
  11. Katz, 2005, Methodological issues in clinical trials of opioids for chronic pain, Neurology, 65, S32, 10.1212/WNL.65.12_suppl_4.S32 · DOI
  12. Portenoy, 2007, Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year Registry Study, Clin J Pain, 23, 287, 10.1097/AJP.0b013e31802b582f · DOI · Paper page
  13. Olsen, 2006, Opioid prescriptions by U.S. primary care physicians from 1992 to 2001, J Pain, 7, 225, 10.1016/j.jpain.2005.11.006 · DOI · Paper page
  14. Clark, 2002, Chronic pain prevalence and analgesic prescribing in a general medical population, J Pain Symptom Manage, 23, 131, 10.1016/S0885-3924(01)00396-7 · DOI · Paper page
  15. Rowbotham, 2007, How effective is long-term opioid therapy for chronic noncancer pain?, Clin J Pain, 23, 300, 10.1097/AJP.0b013e318032de5d · DOI
  16. Mao, 2006, Opioid-induced abnormal pain sensitivity, Curr Pain Headache Rep, 10, 67, 10.1007/s11916-006-0011-5 · DOI
  17. Ossipov, 2005, Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure, Biopolymers, 80, 319, 10.1002/bip.20254 · DOI · Paper page
  18. Rossbach, 1880, Ueber die Gewoehnung an Gifte, Pflugers Arch Gesamte Physiol Menschen, 21, 213, 10.1007/BF01637005 · DOI
  19. Doverty, 2001, Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine, Pain, 93, 155, 10.1016/S0304-3959(01)00306-2 · DOI · Paper page
  20. Compton, 1994, Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status, J Pain Symptom Manage, 9, 462, 10.1016/0885-3924(94)90203-8 · DOI · Paper page
  21. Compton, 2000, Pain responses in methadone-maintained opioid abusers, J Pain Symptom Manage, 20, 237, 10.1016/S0885-3924(00)00191-3 · DOI · Paper page
  22. Dyer, 1999, Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships, Clin Pharmacol Ther, 65, 685, 10.1016/S0009-9236(99)90090-5 · DOI
  23. Schall, 1996, Pain perception of intravenous heroin users on maintenance therapy with levomethadone, Pharmacopsychiatry, 29, 176, 10.1055/s-2007-979567 · DOI
  24. Hood, 2003, Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia, Anesth Analg, 97, 810, 10.1213/01.ANE.0000078811.80093.88 · DOI · Paper page
  25. Angst, 2003, Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal, Pain, 106, 49, 10.1016/S0304-3959(03)00276-8 · DOI · Paper page
  26. Pud, 2006, Opioids and abnormal pain perception: new evidence from a study of chronic opioid addicts and healthy subjects, Drug Alcohol Depend, 82, 218, 10.1016/j.drugalcdep.2005.09.007 · DOI
  27. Martin, 1973, Methadone–a reevaluation, Arch Gen Psychiatry, 28, 286, 10.1001/archpsyc.1973.01750320112017 · DOI · Paper page
  28. Rainville, 1992, A psychophysical comparison of sensory and affective responses to four modalities of experimental pain, Somatosens Mot Res, 9, 265, 10.3109/08990229209144776 · DOI · Paper page
  29. Hay, 2003, Clinical evidence for opioid-induced hyperalgesia., Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 10, 4
  30. Chia, 1999, Intraoperative high dose fentanyl induces postoperative fentanyl tolerance, Can J Anaesth, 46, 872, 10.1007/BF03012978 · DOI · Paper page
  31. Guignard, 2000, Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement, Anesthesiology, 93, 409, 10.1097/00000542-200008000-00019 · DOI · Paper page
  32. Cooper, 1997, Does intrathecal fentanyl produce acute cross-tolerance to i.v. morphine?, Br J Anaesth, 78, 311, 10.1093/bja/78.3.311 · DOI
  33. Joly, 2005, Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine, Anesthesiology, 103, 147, 10.1097/00000542-200507000-00022 · DOI · Paper page
  34. Cortinez, 2001, No clinical evidence of acute opioid tolerance after remifentanil-based anaesthesia, Br J Anaesth, 87, 866, 10.1093/bja/87.6.866 · DOI · Paper page
  35. Lee, 2005, Intraoperative remifentanil infusion does not increase postoperative opioid consumption compared with 70% nitrous oxide, Anesthesiology, 102, 398, 10.1097/00000542-200502000-00024 · DOI
  36. Hansen, 2005, Intra-operative remifentanil might influence pain levels in the immediate post-operative period after major abdominal surgery, Acta Anaesthesiol Scand, 49, 1464, 10.1111/j.1399-6576.2005.00861.x · DOI
  37. Troster, 2006, Modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by parecoxib in humans, Anesthesiology, 105, 1016, 10.1097/00000542-200611000-00024 · DOI
  38. Koppert, 2001, A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine, Anesthesiology, 95, 395, 10.1097/00000542-200108000-00022 · DOI · Paper page
  39. Koppert, 2003, Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans, Anesthesiology, 99, 152, 10.1097/00000542-200307000-00025 · DOI · Paper page
  40. Luginbuhl, 2003, Modulation of remifentanil-induced analgesia, hyperalgesia, and tolerance by small-dose ketamine in humans, Anesth Analg, 96, 726, 10.1213/01.ANE.0000048086.58161.18 · DOI
  41. Compton, 2004, Precipitated opioid withdrawal across acute physical dependence induction methods, Pharmacol Biochem Behav, 77, 263, 10.1016/j.pbb.2003.10.017 · DOI
  42. Chu, 2006, Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study, J Pain, 7, 43, 10.1016/j.jpain.2005.08.001 · DOI · Paper page
  43. Aley, 1995, Opioid and adenosine peripheral antinociception are subject to tolerance and withdrawal, J Neurosci, 15, 8031, 10.1523/JNEUROSCI.15-12-08031.1995 · DOI
  44. Aley, 1997, Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opioid antinociception in rat, J Neurosci, 17, 8018, 10.1523/JNEUROSCI.17-20-08018.1997 · DOI
  45. Aley, 1997, Dissociation of tolerance and dependence for opioid peripheral antinociception in rats, J Neurosci, 17, 3907, 10.1523/JNEUROSCI.17-10-03907.1997 · DOI
  46. Aley, 1997, Multiple receptors involved in peripheral alpha 2, mu, and A1 antinociception, tolerance, and withdrawal, J Neurosci, 17, 735, 10.1523/JNEUROSCI.17-02-00735.1997 · DOI · Paper page
  47. Arts, 1991, Differential contribution of descending serotonergic and noradrenergic systems to central Tyr-D-Ala2-Gly-NMePhe4-Gly-ol5 (DAMGO) and morphine-induced antinociception in mice, J Pharmacol Exp Ther, 256, 890
  48. Liang, 2006, A genetic analysis of opioid-induced hyperalgesia in mice, Anesthesiology, 104, 1054, 10.1097/00000542-200605000-00023 · DOI
  49. Mao, 1994, Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C, J Neurosci, 14, 2301, 10.1523/JNEUROSCI.14-04-02301.1994 · DOI · Paper page
  50. Dunbar, 1998, Repetitive opioid abstinence causes progressive hyperalgesia sensitive to N-methyl-D-aspartate receptor blockade in the rat, J Pharmacol Exp Ther, 284, 678, 10.1016/S0022-3565(24)37250-7 · DOI
  51. Rivat, 2002, Fentanyl enhancement of carrageenan-induced long-lasting hyperalgesia in rats: prevention by the N-methyl-D-aspartate receptor antagonist ketamine, Anesthesiology, 96, 381, 10.1097/00000542-200202000-00025 · DOI · Paper page
  52. Li, 2001, A murine model of opioid-induced hyperalgesia, Brain Res Mol Brain Res, 86, 56, 10.1016/S0169-328X(00)00260-6 · DOI
  53. Sweitzer, 2004, Exaggerated nociceptive responses on morphine withdrawal: roles of protein kinase C epsilon and gamma, Pain, 110, 281, 10.1016/j.pain.2004.04.004 · DOI
  54. Vanderah, 2000, Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance, J Neurosci, 20, 7074, 10.1523/JNEUROSCI.20-18-07074.2000 · DOI · Paper page
  55. Dunbar, 2000, The effect of spinal ibuprofen on opioid withdrawal in the rat, Anesth Analg, 91, 417
  56. Johnston, 2004, A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine, J Neurosci, 24, 7353, 10.1523/JNEUROSCI.1850-04.2004 · DOI · Paper page
  57. Vera-Portocarrero, 2007, Spinal NK-1 receptor expressing neurons mediate opioid-induced hyperalgesia and antinociceptive tolerance via activation of descending pathways, Pain, 129, 35, 10.1016/j.pain.2006.09.033 · DOI
  58. Li, 2002, Hyperalgesia during opioid abstinence: mediation by glutamate and substance p, Anesth Analg, 95, 979, 10.1213/00000539-200210000-00035 · doi:10.1213/00000539-200210000-00035
  59. Belanger, 2002, Expression of calcitonin gene-related peptide, substance P and protein kinase C in cultured dorsal root ganglion neurons following chronic exposure to mu, delta and kappa opiates, Neuroscience, 115, 441, 10.1016/S0306-4522(02)00452-9 · DOI
  60. Mao, 2002, Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity, J Neurosci, 22, 8312, 10.1523/JNEUROSCI.22-18-08312.2002 · DOI · Paper page
  61. Ossipov, 2004, Antinociceptive and nociceptive actions of opioids, J Neurobiol, 61, 126, 10.1002/neu.20091 · DOI · Paper page
  62. Vanderah, 2001, Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance, J Neurosci, 21, 279, 10.1523/JNEUROSCI.21-01-00279.2001 · DOI · Paper page
  63. Xie, 2005, Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance, J Neurosci, 25, 409, 10.1523/JNEUROSCI.4054-04.2005 · DOI · Paper page
  64. Liang, 2006, Genetic variants of the P-glycoprotein gene Abcb1b modulate opioid-induced hyperalgesia, tolerance and dependence, Pharmacogenet Genomics, 16, 825, 10.1097/01.fpc.0000236321.94271.f8 · DOI
  65. Schinkel, 1995, Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A, J Clin Invest, 96, 1698, 10.1172/JCI118214 · DOI · Paper page
  66. Andrews, 1943, The effect of opiates on the pain threshold in post-addicts, J Clin Invest, 22, 511, 10.1172/JCI101420 · DOI
  67. Joshi, 1999, Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia, Anesthesiology, 90, 1007, 10.1097/00000542-199904000-00013 · DOI
  68. Gan, 1997, Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate, Anesthesiology, 87, 1075, 10.1097/00000542-199711000-00011 · DOI · Paper page
  69. Cepeda, 2002, The combination of low dose of naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period, Pain, 96, 73, 10.1016/S0304-3959(01)00425-0 · DOI
  70. Cepeda, 2004, Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects, Pain, 107, 41, 10.1016/j.pain.2003.09.011 · DOI
  71. Kayser, 1987, Paradoxical hyperalgesic effect of exceedingly low doses of systemic morphine in an animal model of persistent pain (Freund's adjuvant-induced arthritic rats), Brain Res, 414, 155, 10.1016/0006-8993(87)91338-2 · DOI
  72. Shen, 1994, Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence, Brain Res, 636, 286, 10.1016/0006-8993(94)91028-6 · DOI
  73. Kayser, 1981, Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats, Brain Res, 226, 344, 10.1016/0006-8993(81)91110-0 · DOI
  74. Woolf, 1980, Analgesia and hyperalgesia produced in the rat by intrathecal naloxone, Brain Res, 189, 593, 10.1016/0006-8993(80)90375-3 · DOI
  75. Smith, 2000, Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites, Clin Exp Pharmacol Physiol, 27, 524, 10.1046/j.1440-1681.2000.03290.x · DOI · Paper page
  76. Wright, 2001, Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide, Life Sci, 69, 409, 10.1016/S0024-3205(01)01133-X · DOI
  77. Sjogren, 1993, Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine, Pain, 55, 93, 10.1016/0304-3959(93)90188-U · DOI
  78. Sjogren, 1994, Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists, Pain, 59, 313, 10.1016/0304-3959(94)90084-1 · DOI · Paper page
  79. Wilson, 2003, Morphine hyperalgesia: a case report, Am J Hosp Palliat Care, 20, 459, 10.1177/104990910302000608 · DOI
  80. De Conno, 1991, Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine, Pain, 47, 337, 10.1016/0304-3959(91)90225-M · DOI · Paper page
  81. Lawlor, 1997, Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study, Pain, 72, 79, 10.1016/S0304-3959(97)00018-3 · doi:10.1016/s0304-3959(97)00018-3
  82. Sjogren, 1998, Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories, Acta Anaesthesiol Scand, 42, 1070, 10.1111/j.1399-6576.1998.tb05378.x · DOI
  83. Heger, 1999, Morphine induced allodynia in a child with brain tumour, BMJ, 319, 627, 10.1136/bmj.319.7210.627 · DOI
  84. Lawlor, 1997, Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence, J Pain Symptom Manage, 13, 356, 10.1016/S0885-3924(97)00081-X · DOI
  85. Parisod, 2003, Allodynia after acute intrathecal morphine administration in a patient with neuropathic pain after spinal cord injury, Anesth Analg, 97, 183, 10.1213/01.ANE.0000068482.67289.1A · DOI
  86. Mercadante, 2003, Hyperalgesia: an emerging iatrogenic syndrome, J Pain Symptom Manage, 26, 769, 10.1016/S0885-3924(03)00258-6 · DOI
  87. Devulder, 1997, Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain, J Neurosurg Anesthesiol, 9, 146, 10.1097/00008506-199704000-00007 · DOI
  88. Mercadante, 2005, Hyperalgesia and opioid switching, Am J Hosp Palliat Care, 22, 291, 10.1177/104990910502200411 · DOI
  89. Guntz, 2007, Opioid-induced hyperalgesia, Eur J Anaesthesiol, 24, 205, 10.1017/S0265021506001700 · DOI
  90. Axelrod, 2007, Using methadone to treat opioid-induced hyperalgesia and refractory pain, J Opioid Manag, 3, 113, 10.5055/jom.2007.0048 · DOI
  91. Ackerman, 2006, Paroxysmal opioid-induced pain and hyperalgesia, J Ky Med Assoc, 104, 419
  92. Chung, 2004, Successful treatment of hydromorphone-induced neurotoxicity and hyperalgesia, Conn Med, 68, 547
  93. Woolf, 1981, Intrathecal high dose morphine produces hyperalgesia in the rat, Brain Res, 209, 491, 10.1016/0006-8993(81)90176-1 · DOI · Paper page
  94. Yaksh, 1988, Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine, J Pharmacol Exp Ther, 244, 501
  95. Yaksh, 1986, High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications, Anesthesiology, 64, 590, 10.1097/00000542-198605000-00008 · DOI · Paper page
  96. Sakurada, 2002, Intrathecal high-dose morphine induces spinally-mediated behavioral responses through NMDA receptors, Brain Res Mol Brain Res, 98, 111, 10.1016/S0169-328X(01)00332-1 · DOI
  97. Hara, 1997, Characterization of nociceptin hyperalgesia and allodynia in conscious mice, Br J Pharmacol, 121, 401, 10.1038/sj.bjp.0701146 · DOI
  98. Dudgeon, 2007, A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients, J Pain Symptom Manage, 33, 365, 10.1016/j.jpainsymman.2006.09.017 · DOI
  99. Galer, 2005, MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance, Pain, 115, 284, 10.1016/j.pain.2005.03.004 · DOI
  100. Orser, 1995, Inhibition by propofol (2,6 di-isopropylphenol) of the N-methyl-D-aspartate subtype of glutamate receptor in cultured hippocampal neurones, Br J Pharmacol, 116, 1761, 10.1111/j.1476-5381.1995.tb16660.x · DOI · Paper page
  101. Grasshoff, 2005, Effects of propofol on N-methyl-D-aspartate receptor-mediated calcium increase in cultured rat cerebrocortical neurons, Eur J Anaesthesiol, 22, 467, 10.1017/S0265021505000803 · DOI
  102. Kingston, 2006, Propofol inhibits phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in neurons, Anesthesiology, 104, 763, 10.1097/00000542-200604000-00021 · DOI
  103. Chen, 2006, The chemical biology of clinically tolerated NMDA receptor antagonists, J Neurochem, 97, 1611, 10.1111/j.1471-4159.2006.03991.x · DOI · Paper page
  104. Snijdelaar, 2004, Effects of perioperative oral amantadine on postoperative pain and morphine consumption in patients after radical prostatectomy: results of a preliminary study, Anesthesiology, 100, 134, 10.1097/00000542-200401000-00022 · doi:10.1097/00000542-200401000-00022
  105. Sang, 2000, NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials, J Pain Symptom Manage, 19, S21, 10.1016/S0885-3924(99)00125-6 · DOI
  106. Mathiesen, 2006, CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model, J Pain, 7, 565, 10.1016/j.jpain.2006.02.004 · DOI
  107. Bassani, 2005, CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats, Eur J Pharmacol, 519, 231, 10.1016/j.ejphar.2005.07.004 · DOI
  108. Astruc, 2005, Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects, Br J Clin Pharmacol, 59, 405, 10.1111/j.1365-2125.2005.02338.x · DOI
  109. Heiskanen, 2002, Analgesic effects of dextromethorphan and morphine in patients with chronic pain, Pain, 96, 261, 10.1016/S0304-3959(01)00455-9 · DOI
  110. Tverskoy, 1994, Preemptive effect of fentanyl and ketamine on postoperative pain and wound hyperalgesia, Anesth Analg, 78, 205, 10.1213/00000539-199402000-00002 · DOI · Paper page
  111. Bell, 1999, Low-dose subcutaneous ketamine infusion and morphine tolerance, Pain, 83, 101, 10.1016/S0304-3959(99)00096-2 · DOI
  112. De Kock, 2001, “Balanced analgesia” in the perioperative period: is there a place for ketamine?, Pain, 92, 373, 10.1016/S0304-3959(01)00278-0 · DOI · Paper page
  113. Ilkjaer, 1996, Effect of systemic N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humans, Br J Anaesth, 76, 829, 10.1093/bja/76.6.829 · DOI
  114. Klein, 2008, Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia, Eur J Pain, 12, 17, 10.1016/j.ejpain.2007.02.002 · DOI
  115. Rammes, 2006, Neramexane (merz pharmaceuticals/forest laboratories), IDrugs, 9, 128
  116. Thisted, 2006, Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study, Clin Ther, 28, 1607, 10.1016/j.clinthera.2006.10.005 · DOI
  117. Williams, 2001, Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action, Curr Drug Targets, 2, 285, 10.2174/1389450013348489 · DOI
  118. Boyce, 1999, Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn, Neuropharmacology, 38, 611, 10.1016/S0028-3908(98)00218-4 · DOI · Paper page
  119. Taniguchi, 1997, Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist, Br J Pharmacol, 122, 809, 10.1038/sj.bjp.0701445 · DOI
  120. Goebel, 1999, NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A, Brain Res Mol Brain Res, 69, 164, 10.1016/S0169-328X(99)00100-X · DOI · Paper page
  121. Zukin, 1995, Alternatively spliced isoforms of the NMDARI receptor subunit, Trends Neurosci, 18, 306, 10.1016/0166-2236(95)93920-S · DOI · Paper page
  122. White, 1996, Pharmacological properties of ketamine, Drug Alcohol Rev, 15, 145, 10.1080/09595239600185801 · DOI
  123. Reich, 1989, Ketamine: an update on the first twenty-five years of clinical experience, Can J Anaesth, 36, 186, 10.1007/BF03011442 · DOI · Paper page
  124. Annetta, 2005, Ketamine: new indications for an old drug, Curr Drug Targets, 6, 789, 10.2174/138945005774574533 · DOI
  125. Sloan, 2002, Anesthetics and the brain, Anesthesiol Clin North America, 20, 265, 10.1016/S0889-8537(01)00002-5 · DOI
  126. Elia, 2005, Ketamine and postoperative pain–a quantitative systematic review of randomised trials, Pain, 113, 61, 10.1016/j.pain.2004.09.036 · DOI · Paper page
  127. Bell, 2006, Perioperative ketamine for acute postoperative pain, Cochrane Database Syst Rev, CD004603
  128. Stubhaug, 1997, Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery, Acta Anaesthesiol Scand, 41, 1124, 10.1111/j.1399-6576.1997.tb04854.x · DOI · Paper page
  129. Bell, 2003, Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review, J Pain Symptom Manage, 26, 867, 10.1016/S0885-3924(03)00311-7 · DOI
  130. Eilers, 2001, The reversal of fentanyl-induced tolerance by administration of “small-dose” ketamine, Anesth Analg, 93, 213, 10.1097/00000539-200107000-00042 · DOI
  131. Zimmermann, 2005, Rotation to methadone after opioid dose escalation: how should individualization of dosing occur?, J Pain Palliat Care Pharmacother, 19, 25
  132. Bowsher, 1993, Paradoxical pain, BMJ, 306, 473, 10.1136/bmj.306.6876.473 · doi:10.1136/bmj.306.6876.473
  133. Skarke, 2005, Is morphine-3-glucuronide of therapeutic relevance?, Pain, 116, 177, 10.1016/j.pain.2005.06.006 · doi:10.1016/j.pain.2005.06.006
  134. Katz, 2000, MorphiDex (MS:DM) double-blind, multiple-dose studies in chronic pain patients, J Pain Symptom Manage, 19, S37, 10.1016/S0885-3924(99)00129-3 · DOI
  135. Caruso, 2000, MorphiDex pharmacokinetic studies and single-dose analgesic efficacy studies in patients with postoperative pain, J Pain Symptom Manage, 19, S31, 10.1016/S0885-3924(99)00128-1 · doi:10.1016/s0885-3924(99)00128-1
  136. Chevlen, 2000, Morphine with dextromethorphan: conversion from other opioid analgesics, J Pain Symptom Manage, 19, S42, 10.1016/S0885-3924(99)00130-X · DOI
  137. Lipton, 1994, Excitatory amino acids as a final common pathway for neurologic disorders, N Engl J Med, 330, 613, 10.1056/NEJM199403033300907 · DOI · Paper page
  138. Rang, 1981, Drugs and ionic channels: mechanisms and implications, Postgrad Med J, 57, 89
  139. Chen, 1992, Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity, J Neurosci, 12, 4427, 10.1523/JNEUROSCI.12-11-04427.1992 · DOI · Paper page
  140. Chen, 1997, Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism, J Physiol, 499, 27, 10.1113/jphysiol.1997.sp021909 · DOI · Paper page
  141. Lipton, 1993, Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide, Trends Neurosci, 16, 527, 10.1016/0166-2236(93)90198-U · DOI · Paper page
  142. Chen, 1998, Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation, Neuroscience, 86, 1121, 10.1016/S0306-4522(98)00163-8 · DOI · Paper page
  143. Ditzler, 1991, Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial, Arzneimittelforschung, 41, 773
  144. Tariot, 2004, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial, JAMA, 291, 317, 10.1001/jama.291.3.317 · DOI · Paper page
  145. Reisberg, 2006, A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease, Arch Neurol, 63, 49, 10.1001/archneur.63.1.49 · DOI · Paper page
  146. Eisenberg, 1995, The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy, Neurosci Lett, 187, 17, 10.1016/0304-3940(95)11326-R · DOI
  147. Carlton, 1995, Treatment with the NMDA antagonist memantine attenuates nociceptive responses to mechanical stimulation in neuropathic rats, Neurosci Lett, 198, 115, 10.1016/0304-3940(95)11980-B · DOI
  148. Chaplan, 1997, Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat, J Pharmacol Exp Ther, 280, 829, 10.1016/S0022-3565(24)36427-4 · DOI · Paper page
  149. Sinis, 2007, Memantine treatment of complex regional pain syndrome: a preliminary report of six cases, Clin J Pain, 23, 237, 10.1097/AJP.0b013e31802f67a7 · DOI
  150. Schifitto, 2006, A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy, J Neurovirol, 12, 328, 10.1080/13550280600873835 · DOI
  151. Sang, 2002, Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials, Anesthesiology, 96, 1053, 10.1097/00000542-200205000-00005 · DOI · Paper page
  152. Eisenberg, 1998, The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study, Eur J Pain, 2, 321, 10.1016/S1090-3801(98)90030-1 · DOI
  153. Nikolajsen, 2000, Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study, Anesth Analg, 91, 960, 10.1097/00000539-200010000-00036 · DOI · Paper page
  154. Chizh, 2001, NMDA receptor antagonists as analgesics: focus on the NR2B subtype, Trends Pharmacol Sci, 22, 636, 10.1016/S0165-6147(00)01863-0 · DOI · Paper page
  155. Ma, 2000, Localization of N-methyl-D-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats, Neuroscience, 101, 699, 10.1016/S0306-4522(00)00419-X · DOI
  156. Wang, 2004, GABAA receptor partially mediated propofol-induced hyperalgesia at superspinal level and analgesia at spinal cord level in rats, Acta Pharmacol Sin, 25, 1619
  157. Baba, 2001, Direct activation of rat spinal dorsal horn neurons by prostaglandin E2, J Neurosci, 21, 1750, 10.1523/JNEUROSCI.21-05-01750.2001 · DOI · Paper page
  158. O'Rielly, 2006, Increased expression of cyclooxygenase and nitric oxide isoforms, and exaggerated sensitivity to prostaglandin E2, in the rat lumbar spinal cord 3 days after L5-L6 spinal nerve ligation, Anesthesiology, 104, 328, 10.1097/00000542-200602000-00019 · DOI
  159. Malmberg, 1992, Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition, Science, 257, 1276, 10.1126/science.1381521 · DOI · Paper page
  160. Yaksh, 1993, Spinal actions of NSAIDS in blocking spinally mediated hyperalgesia: the role of cyclooxygenase products, Agents Actions Suppl, 41, 89
  161. Powell, 1999, Comparative effects of cyclo-oxygenase and nitric oxide synthase inhibition on the development and reversal of spinal opioid tolerance, Br J Pharmacol, 127, 631, 10.1038/sj.bjp.0702587 · DOI
  162. Wong, 2000, Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats, Br J Anaesth, 85, 747, 10.1093/bja/85.5.747 · DOI
  163. Quartilho, 2004, Production of paradoxical sensory hypersensitivity by alpha 2-adrenoreceptor agonists, Anesthesiology, 100, 1538, 10.1097/00000542-200406000-00029 · DOI
  164. Miaskowski, 2002, Oncology outpatients with pain from bone metastasis require more than around-the-clock dosing of analgesics to achieve adequate pain control, J Pain, 3, 12, 10.1054/jpai.2002.27002 · DOI

Cited by

See all 575

Metadata

Authors
Chu, L. F., Angst, M. S., & Clark, D.
Venue
The Clinical Journal of Pain
Published
2008-07
Volume
24
Issue
6
Pages
479-496
ISSN
0749-8047 (ISSN-L)
OpenAlex
W2024836296
Cited by
575
References
16
FWCI
38.79
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Opioid-induced Hyperalgesia in Humans: Molecular Mechanisms and Clinical Considerations. https://app.cochat.ai/papers/10.1097/ajp.0b013e31816b2f43
The paper
Chu, L. F., Angst, M. S., & Clark, D. (2008). Opioid-induced Hyperalgesia in Humans: Molecular Mechanisms and Clinical Considerations. The Clinical Journal of Pain. https://doi.org/10.1097/ajp.0b013e31816b2f43

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.